Not applicableUnknownNCT04931992What this trial is testingOutcome of Patients With CBF and/or NPM1-mutated AML in First Molecular Relapse.Who this might be right forAcute Myeloid Leukemia University Hospital, Angers 100
Early research (Phase 1)Not Yet RecruitingNCT07355335What this trial is testingZiftomenib + Mezigdomide in Adolesc. and Adults w/ R/R AMLWho this might be right forKMT2A-rearrangedNPM1-mutant Refractory or Relapsed AML Massachusetts General Hospital 24
Testing effectiveness (Phase 2)Looking for participantsNCT04988555What this trial is testingEnzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)Who this might be right forLeukemia, Myeloid, AcuteLeukemia, Lymphocytic, AcuteMultiple Myeloma+1 more Sumitomo Pharma America, Inc. 606
Early research (Phase 1)Looking for participantsNCT05735184What this trial is testingInvestigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLWho this might be right forAcute Myeloid LeukemiaMixed Lineage Leukemia Gene MutationRefractory AML+7 more Kura Oncology, Inc. 420
Not applicableLooking for participantsNCT07080970What this trial is testingObservational Study on APL-like aCute Myeloid Leukemia: disTInct Phenotype and Early VAscular complicaTionsWho this might be right forAcute Myeloid LeukemiaNPM1 Mutation Gruppo Italiano Malattie EMatologiche dell'Adulto 220
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07664839What this trial is testingStudy on the Efficacy and Safety of VA Regimen Compared to "3+7" Regimen in Newly Diagnosed AML With NPM1 or IDH1/IDH2 MutationsWho this might be right forAcute Myeloid LeukemiaNPM1 MutationIDH1 Mutation+1 more Shen yang 148
Testing effectiveness (Phase 2)Looking for participantsNCT06424340What this trial is testingMB-dNPM1-TCR.1 in Relapsed/Refractory AMLWho this might be right forLeukemia, Myeloid, Acute Miltenyi Biomedicine GmbH 29
Large-scale testing (Phase 3)Study completedNCT01237808What this trial is testingStudy of Low-Dose Cytarabine and Etoposide With or Without All-Trans Retinoic Acid in Older Patients Not Eligible for Intensive Chemotherapy With Acute Myeloid Leukemia and NPM1 MutationWho this might be right forAcute Myeloid Leukemia (AML) University of Ulm 144
Large-scale testing (Phase 3)Looking for participantsNCT07007312What this trial is testingStudies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AMLWho this might be right forAcute Myeloid Leukemia (AML) Kura Oncology, Inc. 1,300
Early research (Phase 1)Looking for participantsNCT06222580What this trial is testingSNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 MutationWho this might be right forAcute Myeloid Leukemia With FLT3/ITD MutationAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+2 more Uma Borate 30
Early research (Phase 1)Not Yet RecruitingNCT07583303What this trial is testingBSB-2002 After Cyclophosphamide and Fludarabine for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia Patients With NPM1 MutationWho this might be right forRecurrent Acute Myeloid LeukemiaRefractory Acute Myeloid Leukemia City of Hope Medical Center 19
Early research (Phase 1)Looking for participantsNCT05886049What this trial is testingA Phase 1b Study of Menin Inhibitor SNDX- 5613 in Combination With Daunorubicin and Cytarabine in Newly Diagnosed Patients With Acute Myeloid Leukemia and NPM1 Mutated/FLT3 Wildtype or MLL/KMT2A Rearranged or NUP98 Alterations DiseaseWho this might be right forAcute Myeloid LeukemiaAcute Myeloid Leukemia With KMT2A RearrangementAcute Myeloid Leukemia With NPM1 Mutation+1 more National Cancer Institute (NCI) 38
Early research (Phase 1)Looking for participantsNCT07751991What this trial is testingCHM-029 in Participants With NPM1 Mutated, KMT2A or NUP98 Rearranged AMLWho this might be right forAML (Acute Myeloid Leukemia) Charm Therapeutics 40
Large-scale testing (Phase 3)Looking for participantsNCT06652438What this trial is testingRevumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AMLWho this might be right forAcute Myeloid Leukemia, Adult Stichting Hemato-Oncologie voor Volwassenen Nederland 448
Early research (Phase 1)Study completedNCT05326516What this trial is testingRevumenib in Combination With Chemotherapy in Participants With R/R Acute LeukemiaWho this might be right forRelapsed/Refractory LeukemiasAcute Lymphoblastic LeukemiaAcute Lymphocytic Leukemia+3 more Syndax Pharmaceuticals 30
Early research (Phase 1)WithdrawnNCT07566585What this trial is testingDose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 MutationWho this might be right forAML - Acute Myeloid LeukemiaAML With Mutated NPM1AML, Adult Recurrent BlueSphere Bio, Inc
Testing effectiveness (Phase 2)UnknownNCT04689815What this trial is testingOral Arsenic Trioxide for NPM1-mutated AMLWho this might be right forNPMc+ AML The University of Hong Kong 50
Testing effectiveness (Phase 2)Active Not RecruitingNCT06052813What this trial is testingBN104 in the Treatment of Acute LeukemiaWho this might be right forALL, AdultAML, AdultAcute Leukaemia+4 more Institut de Recherches Internationales Servier (I.R.I.S.) 66
Large-scale testing (Phase 3)Ended earlyNCT05020665What this trial is testingEntospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AMLWho this might be right forNucleophosmin 1-mutated Acute Myeloid Leukemia Kronos Bio 15
Testing effectiveness (Phase 2)Looking for participantsNCT05904106What this trial is testingVenetoclax Plus Azacitidine Versus Intensive Chemotherapy for Fit Patients With Newly Diagnosed NPM1 Mutated AMLWho this might be right forAcute Myeloid Leukemia Technische Universität Dresden 146